|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: ZEMPLAR
Summary for Tradename: ZEMPLAR
|
| |||||||||||
Clinical Trials for: ZEMPLARThe Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors Status: Completed Condition: Diabetic Nephropathy; Chronic Kidney Disease The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate Status: Completed Condition: Chronic Kidney Disease Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Status: Completed Condition: Secondary Hyperparathyroidism; Dialysis Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation Status: Completed Condition: Chronic Kidney Disease; Endothelial Dysfunction; Inflammation; Hypertension Oral Paricalcitol in Kidney Transplant Recipients Status: Completed Condition: Transplant; Failure, Kidney; Renal Disease, End Stage; Hyperparathyroidism, Secondary Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Status: Completed Condition: Chronic Kidney Disease; Secondary Hyperparathyroidism; Hemodialysis Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis Status: Completed Condition: Parathyroid Hormone Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis Status: Completed Condition: Chronic Kidney Disease on Hemodialysis; Secondary Hyperparathyroidism Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease Status: Active, not recruiting Condition: Type 2 Diabetes; Chronic Kidney Disease Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery Status: Active, not recruiting Condition: Mucinous Adenocarcinoma of the Rectum; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | ZEMPLAR | paricalcitol | CAPSULE; ORAL | 021606 | May 26, 2005 | RX | No | 5,246,925*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbvie | ZEMPLAR | paricalcitol | CAPSULE; ORAL | 021606 | May 26, 2005 | RX | No | 5,587,497*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbvie | ZEMPLAR | paricalcitol | CAPSULE; ORAL | 021606 | May 26, 2005 | RX | No | 5,597,815*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbvie | ZEMPLAR | paricalcitol | CAPSULE; ORAL | 021606 | May 26, 2005 | RX | Yes | 5,246,925*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: ZEMPLAR
| Drugname | Dosage | Strength | RLD | Submissiondate |
| paricalcitol | Injection | 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials | Zemplar | 11/28/2008 |
| paricalcitol | Capsules | 1 mcg and 2 mcg | Zemplar | 10/14/2008 |
| paricalcitol | Capsules | 4 mcg | Zemplar | 8/25/2008 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc